{
    "2021-06-30": [
        [
            {
                "time": "2021-12-31",
                "original_text": "2021版医保目录申报在即，约40款新药入围！预计明年1月落地执行",
                "features": {
                    "keywords": [
                        "医保目录",
                        "新药",
                        "入围"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "恒瑞医药（600276.SH）：SHR1459片治疗原发性膜性肾病申报临床获批",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "SHR1459",
                        "膜性肾病",
                        "临床获批"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "恒瑞医药（600276.SH）：SHR-1701注射液两个新适应症获批临床",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "SHR-1701",
                        "新适应症",
                        "临床获批"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "恒瑞医药：SHR1459片治疗原发性膜性肾病获批开展床试验",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "SHR1459",
                        "膜性肾病",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "恒瑞医药：子公司SHR-1701注射液获批开展床试验",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "SHR-1701",
                        "子公司",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "投入470 万元！国产眼药离上市又进一步",
                "features": {
                    "keywords": [
                        "国产眼药",
                        "上市",
                        "研发资金"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "“花钱第一名”百济拟登科创板，首家“A+H+N”药企将诞生，募200亿继续砸研发",
                "features": {
                    "keywords": [
                        "百济",
                        "科创板",
                        "A+H+N",
                        "募资",
                        "研发"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "主力尾盘抢筹化工、中药股 抛售生物科技板块",
                "features": {
                    "keywords": [
                        "主力资金",
                        "化工",
                        "中药",
                        "生物科技",
                        "抛售"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "化工",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "恒瑞医药告别“医药一哥”地位，市值较年内高点跌去三成",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "市值下跌",
                        "医药一哥"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-06-29",
                "original_text": "A股融资融券日报：两融余额增加21.38亿元（6月29日）",
                "features": {
                    "keywords": [
                        "两融余额",
                        "增加"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "恒瑞医药连续3日获北向资金净买入",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "北向资金",
                        "净买入"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12-31",
                "original_text": "第五批集采对恒瑞医药的影响",
                "features": {
                    "keywords": [
                        "第五批集采",
                        "恒瑞医药",
                        "影响"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}